- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Video
Case 2: Patient and Provider Educational Needs
Author(s):
Dr Mark Lebwohl provides insight into the educational needs of both patients and providers surround the utilization of spesolimab and its importance in the management of patients with generalized pustular psoriasis.
Mark G. Lebwohl, MD: We just got our first approval for GPP [generalized pustular psoriasis]. For many reasons, this is the best drug because it’s got a track record, it’s published, it’s approved, and it works quickly. Within a week, you’ll see dramatic turnaround. This patient population can be very ill, so clearing GPP quickly is critical. It’s important that we get the word out that we have an approved treatment that works very quickly for GPP. Many of my colleagues still are not aware of it. That’s a mistake. You absolutely should go after GPP and go after it quickly. Figure out what can be given with spesolimab, and be prepared to have the paperwork to get GPP approved and ready to go so you can get it quickly. This is a life-threatening disease.
Transcript edited for clarity
